Pancreatic neuroendocrine tumour
RecruitingA study comparing XL092 versus everolimus in patients with previously treated advanced or metastatic neuroendocrine tumors
A study comparing XL092 versus everolimus in patients with previously treated advanced or metastatic neuroendocrine tumors
- Disease:Pancreatic neuroendocrine tumour
- Substances:EverolimusN-(4-Fluorophenyl)-N-(4-((7-Methoxy-6-(Methylcarbamoyl)Quinolin-4- Yl)Oxy)Phenyl)Cyclopropane-1,1-Dicarboxamide
France- Participants:18–64 years · 65+ years
- Substances:Everolimus
